Mina Makar, senior vice president of respiratory and immunology, Astrazeneca, joined Cheddar to discuss the FDA's decision to give emergency use authorization to the pharma giant's COVID-19 antibody treatment called Evusheld for immunocompromised patients For about 2 percent of the U.S. Makar noted that the injection is supposed to provide antibody protection for those who can't generate their own adequate immune response via the vaccines for a minimum of six months, though long-term trials are underway.
